Premium
Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen
Author(s) -
Matzkin Haim,
Soloway Mark S.,
Schellhammer Paul F.,
Chodak Gerald,
Smith Joseph A.,
Caplan Richard,
Kennealey Gerard T.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930815)72:4<1286::aid-cncr2820720422>3.0.co;2-7
Subject(s) - antiandrogen , medicine , antiandrogens , prostate cancer , oncology , prostatic acid phosphatase , testosterone (patch) , prostate specific antigen , prostate , androgen , cancer , urology , endocrinology , hormone
Abstract Background . Prognostic factors have been shown to be important when stratifying patients with prostate cancer into randomized trials and counseling the individual patient regarding his chances of response to treatment. However, there are no reports on prognostic factors in patients with Stage D2 prostate cancer treated with a pure antiandrogen as monotherapy. Methods . The authors studied a variety of possible prognostic factors among 150 patients with metastatic prostate cancer treated with an antiandrogen (Casodex, Imperial Chemical Industries, Wilmington, DE). Results . In a univariate analysis, performance status; extent of disease (EOD); pretreatment hemoglobin, alkaline phosphatase, prostate‐specific antigen (PSA), and prostatic acid phosphatase (PAP) levels; and extent of disease (EOD) on bone scan all were found to be significant prognostic factors ( P < 0.05). Pretreatment serum testosterone levels, identified as one of the most important prognostic factors, was not identified as significant in the current study. Conclusions . Although the pretreatment testosterone level was shown to be an important prognostic factor in previous studies, using other modes of androgen ablation (reducing testosterone to below castrate levels), the current study suggests it may not be a helpful factor if the therapy used is antiandrogens as monotherapy. This may relate to the different mode of action of antiandrogens, which do not reduce serum testosterone levels.